Certior Financial Group LLC Invests $330,000 in Gilead Sciences, Inc. (NASDAQ:GILD)

Certior Financial Group LLC bought a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 3,572 shares of the biopharmaceutical company’s stock, valued at approximately $330,000.

Several other hedge funds also recently bought and sold shares of GILD. HHM Wealth Advisors LLC lifted its position in shares of Gilead Sciences by 118.5% in the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 154 shares in the last quarter. YANKCOM Partnership purchased a new position in Gilead Sciences in the 4th quarter worth approximately $28,000. Decker Retirement Planning Inc. bought a new position in Gilead Sciences in the 4th quarter worth approximately $29,000. Crews Bank & Trust purchased a new stake in Gilead Sciences during the 4th quarter valued at approximately $31,000. Finally, Stephens Consulting LLC raised its position in shares of Gilead Sciences by 325.0% during the fourth quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 260 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Trading Down 4.6 %

Shares of NASDAQ:GILD opened at $107.25 on Monday. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $119.96. The business has a 50 day moving average of $107.30 and a two-hundred day moving average of $95.98. The company has a market capitalization of $133.54 billion, a PE ratio of 289.86, a PEG ratio of 0.71 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. As a group, analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, March 28th. Stockholders of record on Friday, March 14th were given a dividend of $0.79 per share. The ex-dividend date of this dividend was Friday, March 14th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.95%. Gilead Sciences’s dividend payout ratio (DPR) is 854.05%.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on GILD shares. Wells Fargo & Company lifted their target price on Gilead Sciences from $120.00 to $140.00 and gave the stock an “overweight” rating in a report on Wednesday, March 5th. Royal Bank of Canada raised their target price on shares of Gilead Sciences from $84.00 to $90.00 and gave the stock a “sector perform” rating in a research report on Wednesday, February 12th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $80.00 price objective on shares of Gilead Sciences in a research note on Wednesday, December 11th. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a report on Wednesday, February 12th. Finally, BMO Capital Markets raised their price target on shares of Gilead Sciences from $110.00 to $115.00 and gave the company an “outperform” rating in a report on Wednesday, February 12th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $105.12.

Insider Activity at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total transaction of $228,375.00. Following the transaction, the chief financial officer now owns 129,873 shares in the company, valued at $11,863,898.55. This trade represents a 1.89 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders sold a total of 302,785 shares of company stock worth $30,503,250 in the last 90 days. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.